AUTHOR=Duesman Samuel J. , Ortega-Francisco Sandra , Olguin-Alor Roxana , Acevedo-Dominguez Naray A. , Sestero Christine M. , Chellappan Rajeshwari , De Sarno Patrizia , Yusuf Nabiha , Salgado-Lopez Adrian , Segundo-Liberato Marisol , de Oca-Lagunas Selina Montes , Raman Chander , Soldevila Gloria TITLE=Transforming growth factor receptor III (Betaglycan) regulates the generation of pathogenic Th17 cells in EAE JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1088039 DOI=10.3389/fimmu.2023.1088039 ISSN=1664-3224 ABSTRACT=
The transforming growth factor receptor III (TβRIII) is commonly recognized as a co-receptor that promotes the binding of TGFβ family ligands to type I and type II receptors. Within the immune system, TβRIII regulates T cell development in the thymus and is differentially expressed through activation; however, its function in mature T cells is unclear. To begin addressing this question, we developed a conditional knock-out mouse with restricted TβRIII deletion in mature T cells, necessary because genomic deletion of TβRIII results in perinatal mortality. We determined that TβRIII null mice developed more severe autoimmune central nervous neuroinflammatory disease after immunization with myelin oligodendrocyte peptide (MOG35-55) than wild-type littermates. The increase in disease severity in TβRIII null mice was associated with expanded numbers of CNS infiltrating IFNγ+ CD4+ T cells and cells that co-express both IFNγ and IL-17 (IFNγ+/IL-17+), but not IL-17 alone expressing CD4 T cells compared to